Lu-177

Lutetium-177: PSMA Guided Treatment | #ProstateCancer | #MarkScholzMD | #PCRI

Prostate Cancer Research Institute

Chapter 4: What it's like to have 177 Lutetium PSMA Therapy

ECLIPSE - A Randomized Phase 3 Trial for 177-Lu-PSMA-I&T in patients with mCRPC

Science Animated

Production of n.c.a. Lutetium-177 / EndolucinBeta® for Targeted Radionuclide Therapy

ITM Isotope Technologies Munich SE

Lu-PSMA Radioligand Therapy

University of California Television (UCTV)

Lu177 PRRT For Neuroendocrine Tumors Nets

Nuclear Medicine Therapy

Dr.Gobind Rai Garg discusses the topic - Lutetium LU - 177

Dr. Gobind Rai Garg

Dr. Jonathan R. Strosberg on 177-Lu-Dotatate in Patients With Neuroendocrine Tumors

Targeted Oncology

PSMA Scans & Pluvicto (lutetium-177) in 2022 | Geoffrey Johnson, MD, PhD | PCRI Conference 2022

Prostate Cancer Research Institute

Is Lutetium-177 "Perfect"?

VISION: Lu-177-PSMA-617 in mCRPC

Limitations of Lutetium-177-PSMA & Addressing Treatment Challenges

Treatment for Advanced Prostate Cancer Patients | Lutetium 177 PSMA Radioligand Therapy | Mercy

Mercy Radiology

177 Lu PSMA Treatment for Prostate Cancer (Update: FDA approved on 3/23/22)

Upfront [177Lu]Lu-PSMA-617 radioligand therapy prior to radical prostatectomy in men with HR PC

Cassiopeia- SHINE Lutetium-177 Facility Tour

SHINE Technologies

Key findings from Phase I/II Study: fractionated Lu-177 PSMA therapy shows safety and promise

day2 ksnmmi 2013 - 19 Lu 177 Therapy in Neuroendocrine Tumor

Lutetium-177 (Pluvicto) vs. PSMA-Actinium | #MarkScholzMD #AlexScholz #PCRI

Prostate Cancer Research Institute

April 2023: Dr. Aman Chauhan discusses Phase 2 LUTATHERA (Lu-177) + Triapine Study